Altfest L J & Co. Inc. cut its stake in Pfizer Inc. (NYSE:PFE) by 14.8% in the first quarter, Holdings Channel reports. The institutional investor owned 63,473 shares of the biopharmaceutical company’s stock after selling 11,049 shares during the period. Pfizer makes up about 0.6% of Altfest L J & Co. Inc.’s investment portfolio, making the stock its 27th biggest holding. Altfest L J & Co. Inc.’s holdings in Pfizer were worth $2,696,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Advocacy Wealth Management Services LLC lifted its position in shares of Pfizer by 48.2% during the fourth quarter. Advocacy Wealth Management Services LLC now owns 793 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 258 shares during the last quarter. Winch Advisory Services LLC lifted its position in shares of Pfizer by 69.6% during the fourth quarter. Winch Advisory Services LLC now owns 819 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 336 shares during the last quarter. Ruggie Capital Group bought a new stake in shares of Pfizer during the fourth quarter worth $44,000. Contravisory Investment Management Inc. lifted its position in shares of Pfizer by 182.6% during the fourth quarter. Contravisory Investment Management Inc. now owns 1,153 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 745 shares during the last quarter. Finally, Vestor Capital LLC bought a new stake in shares of Pfizer during the third quarter worth $53,000. Institutional investors own 71.88% of the company’s stock.
In other Pfizer news, insider Alexander R. Mackenzie sold 15,000 shares of Pfizer stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $42.83, for a total value of $642,450.00. Following the transaction, the insider now owns 124,994 shares in the company, valued at $5,353,493.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Pfizer Inc bought 50,000 shares of the business’s stock in a transaction on Monday, May 13th. The stock was bought at an average price of $17.00 per share, for a total transaction of $850,000.00. The disclosure for this purchase can be found here. Company insiders own 0.09% of the company’s stock.
Shares of Pfizer stock traded up $0.26 during trading on Friday, hitting $42.76. 12,521,684 shares of the stock traded hands, compared to its average volume of 20,710,772. The firm has a market cap of $237.74 billion, a P/E ratio of 14.25, a P/E/G ratio of 2.47 and a beta of 0.65. The company has a current ratio of 1.54, a quick ratio of 1.27 and a debt-to-equity ratio of 0.60. Pfizer Inc. has a 52-week low of $35.73 and a 52-week high of $46.47.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, April 30th. The biopharmaceutical company reported $0.85 EPS for the quarter, beating the consensus estimate of $0.75 by $0.10. The firm had revenue of $13.12 billion for the quarter, compared to analyst estimates of $13.01 billion. Pfizer had a return on equity of 27.48% and a net margin of 21.31%. The business’s revenue for the quarter was up 1.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.77 earnings per share. Analysts forecast that Pfizer Inc. will post 2.89 earnings per share for the current year.
The company also recently declared a quarterly dividend, which was paid on Friday, June 7th. Stockholders of record on Friday, May 10th were paid a dividend of $0.36 per share. The ex-dividend date of this dividend was Thursday, May 9th. This represents a $1.44 annualized dividend and a dividend yield of 3.37%. Pfizer’s dividend payout ratio is currently 48.00%.
Several research firms have recently weighed in on PFE. Zacks Investment Research upgraded Pfizer from a “sell” rating to a “hold” rating in a research report on Wednesday, April 3rd. Bank of America lifted their target price on Pfizer from $45.00 to $48.00 and gave the stock a “buy” rating in a research report on Monday, April 1st. Citigroup reiterated a “neutral” rating and set a $41.00 target price on shares of Pfizer in a research report on Wednesday, February 20th. Cantor Fitzgerald reiterated a “buy” rating and set a $53.00 target price on shares of Pfizer in a research report on Tuesday, February 19th. Finally, Goldman Sachs Group began coverage on Pfizer in a research report on Tuesday, May 28th. They set a “conviction-buy” rating for the company. Thirteen research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $46.00.
COPYRIGHT VIOLATION NOTICE: This report was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.dispatchtribunal.com/2019/06/16/altfest-l-j-co-inc-has-2-70-million-position-in-pfizer-inc-nysepfe.html.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Read More: Intrinsic Value
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.